Ozmosi | BAL-200 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

BAL-200

Alternative Names: BAL-200, BAL200
Clinical Status: Active
Latest Update: 2023-01-25
Latest Update Note: News Article

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: inNtRON
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Anthrax

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

01/25/2023

News Article

 iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax

06/06/2022

News Article

 iNtRON Completes GLP-TOX Studies of BAL200

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions